Inhibitors of Phosphoinositol 3 Kinase and NFκB for the Treatment of Chronic Obstructive Pulmonary Disease

Title: Inhibitors of Phosphoinositol 3 Kinase and NFκB for the Treatment of Chronic Obstructive Pulmonary Disease

Volume: 5 Issue: 3

Author(s): Nancy E. Larocca, Dolores Moreno, Jenny V. Garmendia and Juan B. De Sanctis

Affiliation:

Keywords: Alkylamines, azol-pyrimidines derivatives, chronic obstructive pulmonary disease, imidazolines, mTOR inhibitors, NFkb inhibitors, Phosphoinositide 3 kinase, quinazolines, triazoles, spirometry test, lipid kinases, oncogenes

Abstract: Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized mainly by pulmonary airflow limitation that is not fully reversible. New different pharmacological approaches to decrease inflammation of the airways and consequently disease progression and increase airway obstruction reversibility have been developed. In the present article, we review the new patents on phosphoinositide 3 kinase and NFκb inhibitors for future therapies.

Cite this article as:

E. Larocca Nancy, Moreno Dolores, V. Garmendia Jenny and B. De Sanctis Juan, Inhibitors of Phosphoinositol 3 Kinase and NFκB for the Treatment of Chronic Obstructive Pulmonary Disease, Recent Patents on Inflammation & Allergy Drug Discovery 2011; 5 (3) . https://dx.doi.org/10.2174/187221311797264928